Latest Conference Articles

Young adults with psychiatric and behavioral disorders are more likely to experience a decline in sleep intensity and sleep depth more dramatically after adolescence.

George Karpouzas, MD, discusses the results of a study he presented at EULAR 2023 examining associations between bDMARD use and cardiovascular risk later in life.

Pediatric sleep conditions remain understudied.

With a high rate of lost patients, effective treatment is compromised regardless of the success rendered by unattended portable sleep studies, investigators explain.

Risk factors for trouble sleeping identified, including female sex, former smoking, and diabetes, obstructive lung disease, daytime sleepiness, insomnia, nocturia, and/or snorting/gasping/breathing cessation during sleep.

The changes in sleep quality were notably associated with a higher prevalence of obesity indicators in men following the COVID-19 outbreak.

Experiencing everyday discrimination is a significant predictor of sleep-related impairments among Black adults, highlighting the detrimental impact of discrimination.

The results show intraindividual variability in total sleep time, time in bed, midpoint sleep, bedtime, and risetime were associated with lower sleep quality.

“Our findings underline the importance of sleep health in treating depression as the nation battles the current mental health crisis,” investigators write.

A preference for eveningness was significantly associated with worse overall sleep difficulties, longer sleep latency, reduced sleep satisfaction, more prolonged sleep inertia, more daytime naps, and more severe depressive symptomatology.

A new-user, active comparator cohort study from EULAR 2023 suggests use of SGLT2 inhibitors could lower risk of recurrent gout flares in people with type 2 diabetes and gout compared to use of DPP-4 inhibitors.

A pair of studies presented at EULAR 2023 offer perspective on the potential for postpartum depression as well as symptoms of depression and anxiety during pregnancy among women with rheumatic disease.

A group of rheumatologists attending EULAR 2023 provide perspective on their concern regarding the potential threat posed by long COVID in patients with rheumatic disease.

After 12 weeks of treatment, the median sUA levels of patients with gout were reduced from 8.6 mg/dL to 3.6 mg/dL in the AR882 75 mg cohort and 5.0 mg/dL in the AR882 50 mg group.

“These results have significant implications for the scalability of circadian medicine, particularly as consumer-based wearable technology is already commonplace,” investigators explain.

Higher levels of hydrocinnamate and indolepropionate were associated with lower WHIIRS, with stronger associations found in female participants.

The team aimed to examine the impact surgical treatment of obstructive sleep apnea had on periodic limb movement index in pediatric patients.

The results show melatonin levels or phases relative to clock time were not different between healthy individuals and patients with obstructive sleep apnea.

Results of the SELECT-AXIS 2 study supported the efficacy and safety profile of upadacitinib in patients with active ankylosing spondylitis who had an inadequate response to biologic DMARD therapy.

Over a 3-year period, patients treated with upadacitinib reported greater disease improvements and a greater mean change from baseline when compared with those receiving adalimumab.

Response rates in the DISSOLVE I and DISSOLVE II high-dose and low-dose groups receiving SEL-212 were significantly different from the placebo group.

Patients receiving 6MP prophylaxis experienced significantly reduced incidence of arthromyalgia and Health Assessment Questionnaire worsening of 22% or increase of .25.

In patients with systemic lupus erythematosus receiving rituximab and belimumab, Black and Indo-Asian patients were less likely to obtain major clinical response.

An analysis of DECT imaging from the MIRROR trial is providing clinicians with insight into the potential for urate crystal resolution and bone remodeling with pegloticase plus methotrexate in patients with uncontrolled gout.

An analysis of data from the APPLE study provides insight into the heterogeneity that exists within pediatric systemic lupus erythematosus patients.

An analysis of more than 20,000 people with type 2 diabetes suggests initiating therapy with an SGLT2 inhibitor, as a second-line treatment to metformin, was associated with a lower risk of developing gout relative to other second-line therapies.

An analysis of data from the phase 4 MOSAIC trail is providing clinicians with a greater understanding of the effects of apremilast in people with uncontrolled psoriatic arthritis.

Dr. Jean-Pierre Llanos Ackert and Dr. Chris Ambrose discuss the latest data on the breakthrough biologic for severe asthma.

Within the reactive care gout conversations, “pain” and “swelling” were significantly more likely to be mentioned when compared with proactive care conversations.

Brian LaMoreaux, MD, discusses data from an analysis of the MIRROR trial examining the impact of pegloticase plus methotrexate on patient-reported outcomes and quality of life measures among patients with uncontrolled gout.